Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical trial NCT01744626 · COMPLETED

Trial details

NCT number: NCT01744626
Sponsor: Celgene Corporation
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia Lymphocytic Chronic B-Cell

Start date: 2012-12-01
Primary completion: 2015-12-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.